Genocea Biosciences Public Company

Primary contact

Genocea is harnessing the power of T cell immunity to develop life-changing vaccines and immunotherapies. While traditional immunotherapy discovery methods have largely used predictive methods to propose T cell targets, or antigens, Genocea has successfully developed ATLAS, its proprietary high-throughput technology platform, to identify clinically relevant antigens of T cells based on actual human immune responses. The company is currently using ATLAS in immuno-oncology applications to develop neoantigen cancer vaccines, general cancer vaccines and a vaccine targeting cancers caused by Epstein-Barr Virus. Genocea has demonstrated preclinical proof-of-concept with vaccines for herpes simplex virus type 2 (HSV-2), Streptococcus pneumoniae, and Chlamydia trachomatis, infections that affect hundreds of millions of people worldwide.
Primary contact

Funding 💰

Total $209.6M
Select investors JJDC, Skyline Ventures, MP Healthcare Venture Management, Polaris Partners, Lux Capital, SR One, Cycad Group, Auriga Partners, Morningside Group
Last update: May 14, 2018